SGEN
Closed
Seagen Inc
228.74
-0.16 (-0.07%)
Last Update: 22 Dec 2023 17:30:00
Yesterday: 228.9
Day's Range: 228.74 - 228.74
Send
sign up or login to leave a comment!
When Written:
204.7
Seagen Inc. (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies for the treatment of cancer. The company was founded in 1998 and is headquartered in Bothell, Washington.
Seagen's flagship product is Adcetris (brentuximab vedotin), an antibody-drug conjugate (ADC) that targets CD30, a protein expressed on the surface of certain types of cancer cells. Adcetris is approved for the treatment of several types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
In addition to Adcetris, Seagen is developing several other targeted therapies for the treatment of cancer. The company's pipeline includes ADCs, immuno-oncology agents, and small molecule inhibitors.
Seagen has collaborations with several pharmaceutical companies, including Takeda, Genentech, and AbbVie. The company has a global presence, with operations in the United States, Europe, and Asia.
As of 2021, Seagen has a market capitalization of over $26 billion and employs over 2,000 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Seagen's flagship product is Adcetris (brentuximab vedotin), an antibody-drug conjugate (ADC) that targets CD30, a protein expressed on the surface of certain types of cancer cells. Adcetris is approved for the treatment of several types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
In addition to Adcetris, Seagen is developing several other targeted therapies for the treatment of cancer. The company's pipeline includes ADCs, immuno-oncology agents, and small molecule inhibitors.
Seagen has collaborations with several pharmaceutical companies, including Takeda, Genentech, and AbbVie. The company has a global presence, with operations in the United States, Europe, and Asia.
As of 2021, Seagen has a market capitalization of over $26 billion and employs over 2,000 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








